Author

Panagiotis Mistriotis

Auburn UniversityORCID 0000-0002-8069-3278Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Amit MitraiD· 2 shared Farnaz HemmatiiD· 2 shared Farshad AmiriiD· 2 shared Sayak Chakravarti· 2 shared Suman MazumderiD· 2 shared Taraswi Mitra GhoshiD· 2 shared Ujjal Kumar MukherjeeiD· 2 shared Ahmad-Bin Salam· 1 shared

Activity by Year

2022-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Amit MitraORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 30, 2026

Dual inhibition of p38α MAPK and Casein kinase δ/ϵ as a novel treatment strategy for AR-independent and taxane-resistant advanced prostate cancer

Sayak Chakravarti, Suman Mazumder, Farnaz Hemmati…·Amit Mitra

This paper demonstrates that TAK-715, a dual inhibitor of p38α MAPK and casein kinase δ/ϵ, effectively treats taxane-resistant and aggressive prostate cancer by targeting cancer stemness and mitochondrial dysfunction.

DOI 10.64898/2026.09.29.754128

humanbulk RNA-seq

𝕏 PostBluesky

Molecular BiologybioRxivPreprintJul 20, 2022

Integrating pharmacogenomics data-driven prediction with bulk and single-cell RNAseq to demonstrate the efficacy of an NAMPT inhibitor against aggressive, taxane-resistant, and stem-like cells in lethal prostate cancer

Suman Mazumder, Taraswi Mitra Ghosh, Ujjal Kumar Mukherjee…·Amit Mitra

The paper uses scRNAseq and pharmacogenomics to identify FK866 as a potential drug for aggressive prostate cancer, showing its efficacy against drug-resistant and stem-like cells.

5 citations

humanbulk RNA-seq

𝕏 PostBluesky